UNICA IRIS Institutional Research Information System

CHESSA, LUCHINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 219.892
NA - Nord America 14.334
AS - Asia 7.046
SA - Sud America 1.344
Continente sconosciuto - Info sul continente non disponibili 683
AF - Africa 236
OC - Oceania 39
Totale 243.574
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 214.596
US - Stati Uniti d'America 13.986
SG - Singapore 2.771
CN - Cina 2.168
NL - Olanda 1.181
BR - Brasile 1.008
SE - Svezia 876
UA - Ucraina 746
VN - Vietnam 683
DE - Germania 589
GB - Regno Unito 525
FI - Finlandia 518
FR - Francia 386
HK - Hong Kong 330
CA - Canada 194
IN - India 184
BD - Bangladesh 153
KR - Corea 139
AR - Argentina 117
AT - Austria 79
IQ - Iraq 75
MX - Messico 74
ZA - Sudafrica 71
JP - Giappone 64
RU - Federazione Russa 63
ID - Indonesia 59
TR - Turchia 58
PL - Polonia 51
CO - Colombia 50
MA - Marocco 47
EC - Ecuador 46
IE - Irlanda 44
PK - Pakistan 44
ES - Italia 43
AU - Australia 35
VE - Venezuela 35
CL - Cile 33
PH - Filippine 33
SA - Arabia Saudita 32
UZ - Uzbekistan 28
MY - Malesia 27
KE - Kenya 24
CZ - Repubblica Ceca 23
BE - Belgio 22
PY - Paraguay 22
EG - Egitto 20
IR - Iran 20
JM - Giamaica 19
TN - Tunisia 19
AZ - Azerbaigian 17
IL - Israele 17
LT - Lituania 16
TW - Taiwan 16
CH - Svizzera 15
JO - Giordania 15
KZ - Kazakistan 14
AE - Emirati Arabi Uniti 12
PE - Perù 12
RO - Romania 12
TH - Thailandia 12
UY - Uruguay 12
DK - Danimarca 11
DZ - Algeria 10
LB - Libano 10
PA - Panama 10
CR - Costa Rica 9
KG - Kirghizistan 9
MD - Moldavia 9
OM - Oman 9
TT - Trinidad e Tobago 9
AO - Angola 8
HR - Croazia 8
PT - Portogallo 8
RS - Serbia 8
AL - Albania 7
BG - Bulgaria 7
BO - Bolivia 7
GT - Guatemala 7
HN - Honduras 7
LV - Lettonia 7
SY - Repubblica araba siriana 7
GR - Grecia 6
KW - Kuwait 6
BA - Bosnia-Erzegovina 5
BY - Bielorussia 5
HU - Ungheria 5
MK - Macedonia 5
NI - Nicaragua 5
NP - Nepal 5
BH - Bahrain 4
CG - Congo 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
MU - Mauritius 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
PS - Palestinian Territory 4
SI - Slovenia 4
UG - Uganda 4
AP - ???statistics.table.value.countryCode.AP??? 3
Totale 242.832
Salva come PNG Salva come JPEG
Città #
Cagliari 207.718
Uta 5.009
Singapore 1.302
Ashburn 1.253
Dallas 1.198
Amsterdam 1.096
San Jose 954
Fairfield 915
Woodbridge 783
Chandler 735
Boardman 682
Houston 608
Nyköping 520
Ann Arbor 408
Jacksonville 395
Beijing 390
Seattle 362
Helsinki 354
Wilmington 354
Council Bluffs 347
Los Angeles 314
Cambridge 294
Hong Kong 294
Santa Clara 237
New York 231
Ho Chi Minh City 212
Boston 207
Lauterbourg 203
Hefei 196
Dearborn 193
Munich 178
Rome 173
Shanghai 162
The Dalles 152
Nanjing 150
Milan 131
Hanoi 125
Buffalo 123
Seoul 123
São Paulo 102
San Diego 83
Dong Ket 78
Frankfurt am Main 76
Redwood City 73
Orem 72
London 69
Guangzhou 64
Columbus 60
Toronto 58
Mansfield 57
Chicago 55
Nanchang 52
Nuremberg 52
Montreal 49
Tokyo 49
Tianjin 48
Turku 48
Vienna 47
Redondo Beach 46
Atlanta 43
Jiaxing 40
Warsaw 40
Changsha 39
Oxford 38
Shenyang 38
Hebei 37
Brooklyn 36
Paris 36
Phoenix 36
Norwalk 35
Chennai 33
Rio de Janeiro 33
Dublin 32
Johannesburg 32
San Francisco 31
Stockholm 31
Washington 31
Da Nang 30
Denver 30
Baghdad 29
Casablanca 29
Manchester 27
Sassari 27
Haiphong 24
Naples 24
Tashkent 24
Dhaka 23
Orange 23
Verona 23
Belo Horizonte 22
Mountain View 22
Nottingham 22
San Mateo 22
Birmingham 21
Mexico City 21
Nairobi 21
Düsseldorf 20
Santiago 20
Basingstoke 19
Jakarta 19
Totale 231.502
Salva come PNG Salva come JPEG
Nome #
Comparing the responses of countries and National Health Systems to the COVID-19 pandemic: a critical analysis with a case-report series 20.843
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.579
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 3.371
Gastrointestinal Coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management 3.306
HLA-G is highly expressed by plasma cells infiltrating hepatic tissue of patients affected by autoimmune hepatitis 3.150
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ? 3.144
Altered profile of salivary proteins in patients with Autoimmune Hepatitis 2.981
Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible? 2.939
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis 2.836
Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study 2.752
Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients 2.733
Hippocampal axis dysfunction evaluation by Rey-Osterrieth Complex figure test (RCFT) should be included in minimal hepatic encephalopathy (MHE) assessment 2.644
IMPACT OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS ON PROGRESSION OF HEPATOCELLULAR CARCINOMA 2.605
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis 2.553
Behavior of bone mass in long-term HAART patients 2.504
Association of chronic hepatitis C with recurrent brief depression 2.478
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI 2.445
Role of natural killercells receptors on the development and progression of hepatocellularcarcinoma 2.423
Role of HLA-G in autmoimmune hepatitis 2.321
INFLUENZA DEI POLIMORFISMI DELL’INTERFERONE LAMBDA NELLA STORIA NATURALE DELLA INFEZIONE CRONICA DA HBV: COINCIDENZA O REALTÀ? 2.310
Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis 2.230
Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C 2.174
Dynamics of TT virus infection in a cohort of HCV-infected patients achieving sustained virologic responce after treatment with direct-acting antivirals 2.174
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in patients with chronic HCV infection treated with direct antiviral agents 2.034
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 2.029
A multivariate approach for the brain impairment in patients with liver cirrhosi 2.000
La neopterina uraria come marker di attività immunologica nelle malattie infiammatorie croniche dell’intestino 1.958
Is the Inversion in the Trend of the Lethality of the COVID-19 in the Two Hemispheres due to the Difference in Seasons and Weather? 1.932
Efficacy and tolerability of treatment with the new direct acting antivirals (DAAs) in thalassemic patients with chronic Hepatitis 1.921
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 1.829
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in co-infected HIV-HCV patients treated with the new direct acting antivirals (DAAs) 1.773
Long-latency potential study in minimal hepatic hencephalopaty 1.751
null 1.742
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? 1.713
null 1.710
The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study 1.705
The climate in the European Union and the enlarged European Region is a determinant of the COVID-19 case fatality ratio 1.704
null 1.666
SAFETY AND EFFICACY OF PEG-IFN alpha 2a AND RIBAVIRIN FOR TREATMENT OF HEPATITIS C IN SARDINIAN ADULT PATIENTS WITH THALASSEMIA MAJOR: A SINGLE CENTRE REAL LIFE EXPERIENCE 1.661
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 1.646
Multidimensional geriatric assessment in elderly HIV patients 1.635
Evolution of the viral quasispecies tracked by sequence analysis during interferon treatment of chronic hepatitis C. 1.617
null 1.610
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 1.558
The COVID-19 incidence in Italian regions correlates with low temperature, mobility and PM10 pollution but lethality only with low temperature 1.542
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 1.529
HepaDisk – A new quality of life questionnaire for HCV patients 1.522
EVALUATION OF MILD COGNITIVE DYSFUNCTION BY MONTREAL COGNITIVE ASSESSMENT TEST IN PATIENTS WITH CHRONIC HCV INFECTION 1.518
Orthotopic liver transplantation in neurological Wilson desease: case report 1.497
Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection 1.461
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 1.437
Individualized long-term treatment of chronic hepatitis C with interferon alpha (IFN alpha)-2a. 1.425
null 1.424
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 1.387
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 1.369
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination 1.358
Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination 1.344
Evolution of the HCV quasispecies and pattern of response to interferon therapy in patients with chronic hepatitis C 1.332
Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database 1.328
Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort. 1.319
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 1.305
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy 1.287
Can antiretroviral therapy modify the clinical course of HDV infection in HIV positive patients? 1.286
A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population 1.262
La quasispecie del virus dell’epatite C: implicazioni biologiche e cliniche 1.252
null 1.208
Forecasting liver disease burden 1.199
Predictive Factors for Liver Disease Progression Following the Direct Acting Antivirals Induced Sustained Virological Response: Data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) Cohort 1.185
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 1.140
Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy 1.133
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 1.117
A review of the main genetic factors influencing the course of COVID-19 in Sardinia: the role of human leukocyte antigen-G 1.116
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 1.113
Epidemiological and Economic Evaluations According to Daa Treatment Access in Italy Based on Real Life Piter Cohort Data 1.111
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 1.090
Risultati preliminari di uno studio di fase II con Sorafenib in pazienti anziani affetti da epatocarcinoma 1.089
Previous functional social and behavioral rhythms affect resilience to COVID-19-related stress among old adults 1.076
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 1.074
Long term effectiveness of DAA therapy in patients with chronic HCV and Mixed Cryoglobulinemic Syndrome 1.070
Clinical characterization and economic impact evaluation of antiHCV DAA treatment failure:real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) 1.050
Optimization of Hepatitis C Virus screening strategies by birth cohort in Italy 1.050
L'approccio basato sui casi per la diagnosi di malattie epatiche 1.030
Forecasting Hepatitis C liver disease burden based on real life data. Does the hidden iceberg matter to reach the World Health Organization elimination goals? 1.007
Distribution of IL28B polymorphism in a cohort of Italians and immigrants with HCV infection: association with viraemia, stage of fibrosis and response to treatment 995
Mixed cryoglobulinemia: an important but frequently unrecognized and underestimated HCV-related condition in the real life practice 993
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 991
Combined Salivary Proteome Profiling and Machine Learning Analysis Provides Insight into Molecular Signature for Autoimmune Liver Diseases Classification 986
Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resources’ Allocation 962
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 952
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV Gruppo 944
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 940
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study 939
Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study 935
COVID-19 Vaccine Hesitancy among Italian Healthcare Workers: Latent Profiles and Their Relationships to Predictors and Outcome 916
Iron concentration and distribution in the newborn liver 910
Modeling cost-effectiveness and health gains of a “universal“ versus “prioritized“ hepatitis C virus treatment policy in a real-life cohort 903
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 891
The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis 891
Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 890
Covid-19 vaccines work but other factors play a relevant role: a data analysis on spread and mortality in 24 countries 886
Totale 183.655
Salva come PNG Salva come JPEG
Categoria #
all - tutte 337.031
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 337.031
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202211.998 0 1.135 703 1.000 958 985 865 724 1.097 996 1.535 2.000
2022/202319.438 2.076 2.643 2.596 1.408 1.692 1.926 893 1.655 1.133 1.086 1.435 895
2023/202422.027 1.023 1.137 1.230 1.719 2.007 3.667 3.457 1.523 1.022 1.463 1.747 2.032
2024/202558.197 7.306 29.122 5.040 4.491 2.321 2.498 3.731 305 643 1.622 494 624
2025/202614.586 1.015 933 1.898 1.238 1.113 1.207 2.685 723 1.127 1.392 922 333
2026/20271.391 682 709 0 0 0 0 0 0 0 0 0 0
Totale 243.574